Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) EPS (Weighted Average and Diluted): 2019-2024

Historic EPS (Weighted Average and Diluted) for Ocular Therapeutix (OCUL) over the last 6 years, with Dec 2024 value amounting to -$1.22.

  • Ocular Therapeutix's EPS (Weighted Average and Diluted) fell 72.73% to -$0.38 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.43, marking a year-over-year decrease of 17.21%. This contributed to the annual value of -$1.22 for FY2024, which is 19.61% down from last year.
  • Ocular Therapeutix's EPS (Weighted Average and Diluted) amounted to -$1.22 in FY2024, which was down 19.61% from -$1.02 recorded in FY2023.
  • Ocular Therapeutix's 5-year EPS (Weighted Average and Diluted) high stood at -$0.97 for FY2022, and its period low was -$2.56 during FY2020.
  • In the last 3 years, Ocular Therapeutix's EPS (Weighted Average and Diluted) had a median value of -$1.02 in 2023 and averaged -$1.07.
  • Per our database at Business Quant, Ocular Therapeutix's EPS (Weighted Average and Diluted) tumbled by 34.03% in 2020 and then soared by 61.72% in 2021.
  • Ocular Therapeutix's EPS (Weighted Average and Diluted) (Yearly) stood at -$2.56 in 2020, then spiked by 61.72% to -$0.98 in 2021, then grew by 1.02% to -$0.97 in 2022, then fell by 5.15% to -$1.02 in 2023, then dropped by 19.61% to -$1.22 in 2024.